Type 1 Diabetes R&D Center
R&D center in Seattle
In 2012, Novo Nordisk launched a type 1 diabetes R&D Center in Seattle, Washington as part of Novo Nordisk’s Diabetes Research Unit. The unique concept behind the center is to combine basic research and early proof-of-concept trials under one umbrella. Researchers at the center have a mandate to pursue a translational research approach to finding new antigen-based immunological and vaccine treatment advances for type 1 diabetes (T1D) via both in-house and external, public-private collaborations.
In the past decade, type 2 diabetes has been the main focus among diabetes researchers and pharmaceutical companies because of the dramatic rise in the number of people living with the disease. Type 1 diabetes is a different disease that requires life-saving treatment with insulin. Unfortunately, there has been a lack of major scientific progress in this area in recent years.
It has been a part of Novo Nordisk’s mission from its inception in the early 1920’s to research and develop interventions for the prevention, treatment and ultimately, the cure, of diabetes. Initiation of this new R&D center re-emphasises the company’s commitment in this specific disease area.
Internationally-renowned leader brings collaborative research approach
Matthias von Herrath, MD, a world-renowned researcher in auto-immune diseases and winner of the 2008 American Diabetes Association Outstanding Scientific Achievement Award, serves as Director of the Type 1 Diabetes R&D Center. Dr. von Herrath, who still holds a part-time faculty position at this former institution,La Jolla Institute for Allergy and Immunology, also serves as president of both the Immunology of Diabetes Society (IDS) and the Clinical Immunology Society (CIS).
His dream is to use translational research methods to accelerate clinical testing of promising combinations of new antigen-based therapies and vaccines early in the treatment development process.